These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11088048)

  • 41. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The relationship between the receptor status and the mammographic picture in operable breast cancer].
    Ventrella V; Paradiso A; Farchi G; Tommasi S; Schittulli F; Racanelli A; De Lena M
    Radiol Med; 1990 May; 79(5):483-8. PubMed ID: 2359855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
    Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
    Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India.
    Rajan G; Culas TB; Jayalakshmy PS
    World J Surg Oncol; 2014 Apr; 12():120. PubMed ID: 24761803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
    Chapman JW; Bayani J; SenGupta S; Bartlett JMS; Piper T; Quintayo MA; Virk S; Goss PE; Ingle JN; Ellis MJ; Sledge GW; Budd GT; Rabaglio M; Ansari RH; Tozer R; D'Souza DP; Chalchal H; Spadafora S; Stearns V; Perez EA; Gelmon KA; Whelan TJ; Elliott C; Shepherd LE; Chen BE; Taylor KJ
    J Clin Oncol; 2024 Aug; 42(24):2887-2898. PubMed ID: 38824432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The nontransformed progesterone and estrogen receptors in gastric cancer.
    Wu CW; Chang HM; Kao HL; Lui WY; P'eng FK; Chi CW
    Gastroenterology; 1992 May; 102(5):1639-46. PubMed ID: 1373695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Expression of steroid receptors and DNA synthesis in male breast cancer].
    Petroni S; Mangia A; D'Amico C; Simone G
    Pathologica; 2003 Feb; 95(1):31-6. PubMed ID: 12735283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
    Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
    J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report).
    Nardelli GB; Lamaina V; Siliotti F
    Eur J Gynaecol Oncol; 1986; 7(3):151-8. PubMed ID: 3536517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Receptor status (ER and PgR) determined with histochemical and biochemical methods in breast carcinoma].
    Simone G; Paradiso A; Cirillo R; Mangia A; Rella G; Wiesel S; Petroni S; De Benedictis G; De Lena M
    Pathologica; 1991; 83(1086):449-59. PubMed ID: 1724316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
    Lundgren S; Søreide JA; Lea OA
    Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours.
    Pichon MF; Milgrom E
    Br J Cancer; 1992 Jun; 65(6):895-7. PubMed ID: 1616860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival.
    Pertschuk LP; Kim DS; Nayer K; Feldman JG; Eisenberg KB; Carter AC; Rong ZT; Thelmo WL; Fleisher J; Greene GL
    Cancer; 1990 Oct; 66(8):1663-70. PubMed ID: 2208020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
    Suzuki R; Ye W; Rylander-Rudqvist T; Saji S; Colditz GA; Wolk A
    J Natl Cancer Inst; 2005 Nov; 97(21):1601-8. PubMed ID: 16264180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: evaluation of discordant findings.
    Stierer M; Rosen H; Weber R; Hanak H; Auerbach L; Spona J; Tüchler H
    Breast Cancer Res Treat; 1998 Jul; 50(2):125-34. PubMed ID: 9822217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.